Angiogenesis, extracellular matrix remodeling and cell migration are associated with cancer progression and involve at least, the plasminogen activating system and its main physiological inhibitor, the plasminogen activator inhibitor-1 (PAI-1). Considering the recognized importance of PAI-1 in the regulation of tumor angiogenesis and invasion in murine models of skin tumor transplantation, we explored the functional significance of PAI-1 during early stages of neoplastic progression in the transgenic mouse model of multistage epithelial carcinogenesis (K14-HPV16 mice). We have studied the effect of genetic deletion of PAI-1 on inflammation, angiogenesis, lymphangiogenesis, as well as tumor progression. In this model, PAI-1 deficiency neither impaired keratinocyte hyperproliferation or tumor development, nor affected the infiltration of inflammatory cells and development of angiogenic or lymphangiogenic vasculature. We are reporting evidence for concomitant lymphangiogenic and angiogenic switches independent to PAI-1 status. Taken together, these data indicate that PAI-1 is not rate limiting for neoplastic progression and vascularization during premalignant progression, or that there is a functional redundancy between PAI-1 and other tumor regulators, masking the effect of PAI-1 deficiency in this long-term model of multi-stage epithelial carcinogenesis.
INTRODUCTION
The plasminogen activator system plays a crucial role in tumor initiation, growth, invasion, angiogenesis and metastasis formation 1 . This proteolytic system is composed of the cellular receptor of urokinase (uPAR), the urokinase-type (uPA) and tissue-type plasminogen (tPA) activators and their specific inhibitor, the plasminogen activator inhibitor-1 (PAI-1) 2-3 .
Consistent with their role in cancer progression, high levels of uPA, PAI-1 and uPAR correlate with adverse patient outcome 1 . A large body of clinical data led to the statement that uPA and PAI-1 are among the first biological prognostic factors to have their clinical value validated 4 . PAI-1 over-expressed in tumors 5 is preferentially localized in the stromal area [6] [7] .
It is expressed by various cell types including endothelial cells 8 , mast cells 9 , fibroblasts 10 and myofibroblasts 11 .
Beside regulating proteolytic cascades during tissue remodeling, PAI-1 also modulates cell adhesion by interfering with integrin, vitronectin and low density lipoprotein receptor related protein (LRP) [12] [13] [14] [15] . In addition, it regulates cell proliferation [16] [17] and cell apoptosis 18 .
PAI-1 is thus a multifunctional protein displaying paradoxical functions during tumor progression 1-3-13 .
The effect of PAI-1 on tumor biology has been explored by using transgenic mice deficient for PAI-1 or over-expressing PAI-1 1-14-19 . This approach clearly underlined two distinct effects of PAI-1 on tumor angiogenesis. While high levels of PAI-1 inhibited angiogenesis, physiological levels of PAI-1 were required for in vitro 20 and in vivo angiogenesis [21] [22] [23] . In addition, PAI-1 produced by host cells plays an important role in human carcinoma progression 24 . These data derived from experimental tumor transplantation models in which tumor cells were transplanted into syngeneic mice genetically modified to overproduce or be deficient in PAI-1 expression are not consistent with the observations made with de novo carcinogenesis models. Indeed, PAI-1 deficiency did not affect cancer progression in a transgenic mouse model of mammary carcinogenesis, the MMTV-PymT mice 25 . In addition, we have recently reported that PAI-1 has no effect on primary ocular tumor growth, but reduces brain metastasis in TRP-1/SV40 transgenic mice 26 . It is not clear whether PAI-1-induced tumor angiogenesis represents a direct intrinsic response to invasive cancer cells or an early response to inflammatory assault that induces the angiogenic switch and subsequent malignant conversion. It has become evident that early and persistent inflammatory responses observed in or around developing neoplasms influence tumor progression 27 . Several studies have shown the production of PAI-1 by immune cells such as macrophages and mast cells [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . In addition, PAI-1 inhibits the phagocytosis of apoptotic neutrophils (efferocytosis) and potentiates neutrophil activation [29] [30] . Although the implication of PAI-1 in inflammation is clear, the putative contribution of PAI-1 in tumor-associated inflammation is not fully understood.
With the aim at evaluating the contribution of PAI-1 during the premalignant stages of carcinoma development, we used a well established transgenic mouse model of de novo epithelial squamous cell carcinogenesis 31 . In this model, expression of early region genes (E6 and E7) of the human papillomavirus type 16 in basal keratinocytes driven by keratin 14 promoter/enhancer induces epithelial carcinogenesis through well-defined premalignant stages before de novo carcinoma development (e.g. K14-HPV16 mice). K14-HPV16 mice develop hyperplastic skin lesions with 100% penetrance by 1 month of age that focally progress to dysplasia by 3 to 6 months 31 . Dysplastic tissues undergo malignant conversion into squamous cell carcinoma (SCC) in skin of 50% of mice (FVB/n, N25), 30% of which metastasize into draining lymph nodes [31] [32] . This model has called attention to the involvement of proteases produced by mast cells 33 and other bone marrow-derived cells (neutrophils and macrophage) in the development of angiogenic vasculature and tumor development 34-34-35 . In the current study, we have examined the functional significance of PAI-1 in tumor-associated inflammation, development of angiogenic and lymphangiogenic vessels occurring during the course of carcinoma development. Our data indicate that PAI-1 independent pathways are critical for the onset and maintenance of chronic inflammation, angiogenesis and lymphangiogenesis during the early stages of epithelial carcinogenesis.
MATERIAL AND METHODS

Transgenic mice.
Generation and characterization of K14-HPV16 transgenic mice on the FVB/n genetic background has been described previously [31] [32] [33] [34] [35] [36] . 
Reverse Transcriptase-PCR analysis
RT-PCR amplification was carried out with the GeneAmp Thermostable rTth reverse transcriptase RNA PCR kit (Perkin Elmer Life Sciences, Boston, MA) with specific pairs of primers (Table I) . RT-PCR products were resolved by electrophoresis in 10% polyacrylamide gels and analyzed with a Fluor-S MultiImager after staining with Gelstar dye (FMC BioProducts, Heidelberg, Germany). RT-PCR products were quantified by normalization with respect to 28S rRNA. Statistical differences between experimental groups were assessed by using Mann-Whitney with GraphPad Prism 4.0 (San Diego, Ca, USA.). Statistical significance was set as P<0,05.
Quantification and statistical analysis
Quantification assisted by computer
Micrographs of tissue section were digitized in the RGB space from optical microscope images captured at 5X magnification. In this representation, the lymphatic vessels stained as described above, appeared in the red colour. In order to quantify lymphangiogenesis, RGB images where decomposed into their red (R), green (G) and bleu (B) components and the red component images were thresholded using a non-parametric method. After this transformation, binary images were obtained in which vessels were represented by white pixels (intensity equal to 1) and the background by black pixels (intensity equal to 0). On these binary images, different parameters were evaluated: (1) the mean surface of vessels, (2) the number of vessels par unit of tissue area, and (3) the percent of tissue occupied by vessels (area density of vessels).
RESULTS
PAI-1 deficiency does not affect the characteristic parameters of premalignant carcinogenesis in K14-HPV16 mice
Previous studies using K14-HPV16 mice revealed an important role for the angiogenic switch during skin carcinoma progression 33 . penetrance, HV16 mice of both genotypes developed hyperplastic skin lesions by 1 month of age followed by the development of dysplasias by 4 to 6 months of age. The latency and the incidence of the lesions observed in ear skin were independent of PAI-1 status. In both genotypes, we detected 100% of hyperplastic lesions by one month of age (n = 10) and 100%
of dysplastic lesions at 4 months (n=22) and at 6 months (n=28) of age
As an intrinsic property of many neoplastic cell types, keratinocyte hyperproliferation is a characteristic of neoplastic progression in K14-HPV16 mice 33-36-37 . Keratinocyte proliferative indices were determined by Ki67 staining in age-matched skin from K14-HPV16/PAI-1 +/+ and K14-HPV16/PAI-1 -/-mice and were found to be similar in each neoplastic stages examined (Figure 1, P>0.1) . Altogether, these observations suggest that PAI-1 is not involved in the control of epithelial hyperproliferation and in early stages of premalignant progression.
PAI-1 deficiency does not affect the (lymph)angiogenic switch in K14-HPV16 mice
In K14-HPV16 mice, changes in vascular architecture reflect the phenotypic switch to A "lymphangiogenic switch" in tumors might represent a mirror image of an angiogenic switch induced by an imbalance between lymphangiogenic factors and inhibitors in favour of activators [38] [39] . Lyve-1 staining was performed to identify lymphatic vessels and revealed dramatic changes in dermal lymphatic density and architecture associated with premalignant progression. Normal non transgenic mouse skin contained infrequent lymphatic vessels ( Figure 3A) . Hyperplastic lesions showed a modest increase in the density and dilatation of lymphatic vessels ( Figure 3C ). Dysplastic lesions contained dilated and enlarged vessels that were increased in number ( Figure 3D ). This vascular pattern is indicative of a lymphangiogenic switch and is in line with previous studies 40 . Nevertheless, no significant difference in the number of lymph vessels was found between K14-HPV16 PAI-1 -/-and K14-HPV16 PAI-1 +/+ in age-matched mice at 1, 4 and 6 months ( Figure 3F, P>0.3) . To compare the area of dilated vessels present in dysplatic lesions between K14-HPV16 PAI-1 -/-and K14-HPV16 PAI-1 +/+ , we performed a quantitative analysis on ear skin from mice at 4 months of age ( Figure 3G and 3H, P>0.1). No difference was observed between the two genotypes.
Altogether, these data indicate that PAI-1 deficiency does not influence either the angiogenic switch or the lymphangiogenic switch observed early in premalignant skin of K14-HPV16 mice.
PAI-1 deficiency does not affect the infiltration of inflammatory cells in K14-HPV16 mice
The K14-HPV16 transgenic model is characterized by an increased infiltration of CD45 positive immune cells in the successive neoplastic stages. In the opposite to hyperplasia, dysplastic lesions are infiltrated by mast cells, macrophages and neutrophils close to dilated and enlarged angiogenic vasculature 33-37-41 . We profiled the infiltration of leukocytes and mast cells in neoplastic tissue from K14-HPV16 PAI-1 -/-and K14-HPV16 PAI-1 +/+ mice aged of 1, 4 and 6 months by immunohistochemistry. Visual detection of leukocytes performed by CD45 staining did not reveal differences in leukocyte infiltration between the two genotypes (data not shown).
Through toluidin blue coloration, we detected mast cells in tissue. In accordance with previous observations, mast cell numbers increased progressively in the dermal connective tissue at the hyperplastic (1-month old) and dysplastic (4-6 months old) stages ( Figure 4F ).
However, the number of mast cells infiltrating the lesions was similar in mice irrespective of their PAI-1 status (Figure 4 , P>0.3). We confirmed these results by chloroacetate esterase (CAE) histochemistry which detects serine esterase activity in mast cells (data not shown).
The lack of difference in immune cell infiltration between the two genotypes indicates that this process is not influenced by PAI-1 status.
PAI-1 deficiency is not compensated by the overexpression of the main related proteases or inhibitors
In order to address the possibility that other components of related proteolytic systems might compensate for the absence of PAI-1, we performed mRNA expression analysis by semi-quantitative RT-PCR of the genes encoding several protease related candidates (Table   I ). The molecules studied included components of the plasminogen/plasmin system (tPA, identify it as a potential therapeutic target 1-48-49 . Indeed, PAI-1 deficiency in mice has been reported to dramatically reduce angiogenesis in different models of tumor transplantation [21] [22] .
In addition, PAI-1 displays a pro-angiogenic effect in other angiogenesis model such as the mouse aortic ring assay 20 and the laser-induced choroidal neoangiogenesis model 50 .
Such a discrepancy or apparently contradiction could be explained by some differences that exist between the models used. It is possible that tumor growth and vascularization are governed by other processes during the development of tumors upon carcinogenesis than those provoked by the inoculation or transplantation of tumor cells which represents an acute response as opposed to de novo tumor development. In carcinogenesis models, the impact of a genetic ablation is evaluated during the whole process of cancer progression and dissemination, while it is temporally assessed in transplantation models. Alternatively, a functional overlap between MMP and PA systems has been demonstrated in wound healing 51 . We therefore searched for other compounds of PA, MMP proteolytic systems and angiogenic factors (FGF1, VEGF) putatively involved in angiogenesis. However, we found no evidence that PAI-1 deficiency led to a compensatory increase in the levels of proteases (tPA, uPA, uPAR, MMP-2, MMP-9 and MMP-13) or angiogenic factors (FGF1, VEGF).
Compensatory increase in (an
Differential data generated with carcinogenesis models and tumor transplantation could also rely on the important influence of various host and/or tumor factors such as for instances, cell numbers, cell types (carcinoma versus fibrosarcoma; poorly tumorigenic versus aggressive tumor cells), stages of malignancy studied, expression of other modulators and site of inoculation . In addition, it is worth noting that the two investigations using mammary and skin multistage carcinogenesis models of MMTV-PymT-induced mammary gland carcinoma 25 and the K14-HPV-16 skin squamous carcinoma model (the present study) reveal the lack of PAI-1 deficiency impacts on neoplastic progression and vascular density. These two transgenic mice have similar FVB/N background while the pro-angiogenic and protumorigenic effects of PAI-1 were observed in C57BL/6 21-22-53 and Rag-1 -/-/C57BL/6 [18] [19] [20] [21] [22] [23] [24] .
There are accumulating reports of strain-related polymorphisms differentially affecting phenotypes in mouse carcinogenesis models . The phenotyping of K14-HPV16 mice in different backgrounds revealed that C57BL/6 mice are the most resistant, developing only hyperplasia, whereas BALB/c develop dysplasia and papillomas and only FVB/n mice are permissive for malignant conversion 31 . Similarly, C57BL/6 strain is resistant to the development of Hras-induced SCC whereas FVB/N mice are highly susceptible 55 . A strong effect of strain on tumor latency and timing of metastasis has also been reported for PymT mice [56] [57] . In this context, a recent study has demonstrated that the anti-metastatic outcome of MMP-9 deficiency is dependent on the strain used 54 . Only mice that had a genetic background derived from C57BL/6 showed reduced metastasis in the absence of MMP9, whereas mice of the FVB/n background showed no differences after genetic ablation of the enzyme. Analysis of strain-dependent modifiers has identified Sipa1 gene on chromosome 19
and Patched gene on chromosome 13 as likely candidates for MMTV-PyMT metastasis and SCC susceptibility in FVB/N strain, respectively [55] [56] [57] [58] . Other loci related to tumor susceptibility might also be present on chromosomes 6, 9, 13, 17 and 19 59 . The possibility that PAI-1 gene is itself the gene that is polymorphic is unlikely since it is located on chromosome 5. Further in-depth genetic studies are required to investigate the putative implication of other strain-dependent genes coding for PAI-1 partners such as proteases, ECM components, adhesion molecules.
PAI-1 is a multi-functional molecule displaying, some time, opposite functions during cancer progression on cell migration, apoptosis, proliferation and extracellular matrix proteolysis. The ability of PAI-1 to regulate cell proliferation and migration has been attributed to its ability to control plasmin production, to modify signaling pathways and to bind to uPAR, vitronectin, integrin and lipoprotein receptor related protein 
